| Notes |
"Dr Paul Cuddon
Healthcare and Life Sciences Research Analyst, London
Paul began his career as a PhD Student at the Babraham Institute in Cambridge studying the biology of neural networks and spent a year with Merck, Sharp and Dohme working on neural stem cells. He then undertook a postdoc at the Cambridge Institute of Medical Research discovering potential treatments for Huntington’s Disease.
He moved into equity research in 2007, and has been a top-ranked Healthcare Analyst for the last decade. He has written extensively on diagnostics for SARS-CoV-2 treatments and vaccines for COVID-19 and the collateral impact of the pandemic on a variety of business and healthcare services. His input into HART is in his personal capacity."
https://web.archive.org/web/20210125154129/https://www.hartgroup.org/bios/ |